BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 15866680)

  • 21. Neoral dose adjustment after conversion from C0 to C2 monitoring in stable renal transplant recipients: a prospective single center study.
    Sandrini S; Bossini N; Setti G; Mazzucchelli C; Maiorca P; Cancarini G
    J Nephrol; 2004; 17(2):284-90. PubMed ID: 15293530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL; Tona F; Piaserico S; Gambino A; Feltrin G; Fortina AB; Angelini A; Alaibac M; Bontorin M; Calzolari D; Peserico A; Thiene G; Iliceto S; Gerosa G
    Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.
    Hecking M; Kainz A; Schillinger M; Posch C; Birsan T; Rasoul-Rockenschaub S; Böhmig GA; Schmaldienst S; Watschinger B; Hörl WH; Mühlbacher F; Säemann MD
    Transpl Int; 2008 Mar; 21(3):223-33. PubMed ID: 17903183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients.
    Jorga A; Holt DW; Yaqoob M; Whittaker C; Johnston A
    Transplant Proc; 2004 Dec; 36(10):3239-41. PubMed ID: 15686737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
    Loichot C; Bentue-Ferrer D; Bernard N; Bonardet A; Boulieu R; Kergueris MF; Paintaud G; Peytavin G; Simon N; Marquet P;
    Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation.
    Glanville AR; Morton JM; Aboyoun CL; Plit ML; Malouf MA
    J Heart Lung Transplant; 2004 Oct; 23(10):1170-4. PubMed ID: 15477111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
    Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
    Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
    Aros CA; Schneider HO; Flores CA; Ardiles LG; Alruiz PA; Jerez V; Mezzano SA
    Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of renal function improvement following tacrolimus conversion in cyclosporine-treated kidney transplant recipients.
    Chang HR; Lin CC; Lian JD
    Transplant Proc; 2007 Dec; 39(10):3135-41. PubMed ID: 18089339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients.
    Li J; Dahmen U; Beckebaum S; Cicinnati V; Valentin-Gamazo C; Frilling A; Malago M; Broelsch CE
    Eur J Med Res; 2006 Apr; 11(4):139-45. PubMed ID: 16720277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
    Higgins RM; Kanji H; Hernon M; Harrison P; Lam FT; Kashi SH
    Transpl Int; 2005 Jul; 18(7):806-10. PubMed ID: 15948859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of cyclosporine C2 levels in long-term stable renal allograft recipients.
    Hu RH; Tsai MK; Lee PH
    Transplant Proc; 2004 Sep; 36(7):2105-7. PubMed ID: 15518762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclosporine C2 levels in de novo renal allograft recipients: a German multicenter prospective observational study.
    Arns W; Zantvoort F; Abendroth D; Seiter H; Scheuermann EH; Albert U; Stahl R; Fornara P; Fricke L; Neumayer HH; Nagel E; Michel U; Ulbricht B
    Transplant Proc; 2005 Apr; 37(3):1612-5. PubMed ID: 15866687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation.
    Morton JM; Aboyoun CL; Malouf MA; Plit ML; Glanville AR
    J Heart Lung Transplant; 2004 Sep; 23(9):1035-9. PubMed ID: 15454168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can cyclosporine blood level be reduced to half after heart transplantation?
    Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
    Transplant Proc; 2010 Apr; 42(3):930-3. PubMed ID: 20430207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
    Videla CO
    Transplant Proc; 2009; 41(6):2659-63. PubMed ID: 19715995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.